Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EABR | ISIN: IT0003828271 | Ticker-Symbol: RER1
Tradegate
15.05.25 | 09:30
50,45 Euro
+0,10 % +0,05
1-Jahres-Chart
RECORDATI SPA Chart 1 Jahr
5-Tage-Chart
RECORDATI SPA 5-Tage-Chart
RealtimeGeldBriefZeit
50,9551,4019:38
50,9551,4019:38

Aktuelle News zur RECORDATI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMilan: Major selling for Recordati-
08.05.Recordati reports Q1 results5
08.05.Recordati stock rises following 1Q earnings beat3
08.05.Recordati-Aktie steigt nach besserem Ergebnis im ersten Quartal3
08.05.Recordati: RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%205Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 270.2 million, +10.7%, margin...
► Artikel lesen
RECORDATI Aktie jetzt für 0€ handeln
07.05.Milan: Downbeat day for Recordati-
01.05.Italy's private debt & corporate finance weekly round-up. News from Lottomatica, Aeroporti di Roma, Recordati, and more2
30.04.Milan: Recordati moves up-
28.04.Recordati: RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION360RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND...
► Artikel lesen
16.04.Recordati: RECORDATI: FDA GRANTS ISTURISA (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME296RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME ISTURISA® is a cortisol synthesis inhibitor...
► Artikel lesen
19.03.Deutsche Bank lifts Recordati stock rating to hold; target at €526
24.02.Italy's private equity weekly roundup. News from Plenitude, ENI, Acea Energia, KKR, Apollo Global Management, Ares Management, Stonepeak, Trilantic Europe, HitecVision, Enilive, KKR, CVC, Recordati, and more9
19.02.Recordati-Aktie bricht nach Ankündigung von Anteilsverkauf ein 17
19.02.Recordati stock falls on stake sale news3
13.02.Recordati reports prelim FY results and provides FY outlook3
13.02.Recordati meldet solide Ergebnisse2
13.02.Recordati reports solid results4
13.02.Recordati: RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS352RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidated net revenue...
► Artikel lesen
07.02.Recordati stock rating cut to sell by Deutsche Bank16
02.12.24Italy's private equity weekly roundup. News from Recordati, Angelini, CVC, Omnia Technologies, Guala Closures, Investindustrial, and more7
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1